Recombinant monoclonal antibody to Abeta. Ponezumab is a humanized monoclonal antibody designed for the treatment of Alzheimer's disease.
Figure 1 Quantification of individual cerebral vessels intravital multiphoton microscopy.
Quantification of cerebral vessels from PSAPP mice (6 months of age,n= 6–7 per group) imaged over a 3-month period and following chronic administration of ponezumab (blue, 10 mg/kg weekly, intraperitoneal) or vehicle (red). For the normalized fraction of positive voxels we found that only time was a significant covariate. Planned comparisons revealed that relative to baseline, the level was significantly higher at 1 month [t(56) = 3.45,P50.003] and at 3 months for the vehicle treated group only. Following ponezumab administration there was no statistically significant differences [t(56) = 1.5,P50.29 andt(56) = 1.04, P<0.55, for 1 and 3 months, respectively]. Data are represented as mean SEM. ***P<0.001 (A). Representative images following dextran labelling of vasculature (blue) with methoxy-034-labelled amyloid (magenta) following vehicle (B) or ponezumab administration (C) for 3 months. Scale bar = 100mm.
Bales, K. R., O’neill, S. M., Pozdnyakov, N., Pan, F., Caouette, D., Pi, Y., ... & Johnson, A. W. (2015). Passive immunotherapy targeting amyloid-β reduces cerebral amyloid angiopathy and improves vascular reactivity. Brain, 139(2), 563-577.
Figure 2 Quantification of amyloid-band amyloid in cerebral vessels following administration of ponezumab.
Significant reduction in Congo red-positive amyloid in leptomeningeal (A) and brain vessels (B). Significant reduction in the number of leptomeningeal (C)or brain vessels (D) immunoreactive for amyloid-b40following administration of ponezumab. PSAPP mice (6 months of age at study start) were treated for 6 months with ponezumab (10 mg/kg; weekly intraperitoneal; n= 6–9 mice per group). The number of vessels (average number/section/mouse) that were stained (550% coverage) were plotted for each section analysed (6–9 sections analysed per animal). Data are represented as mean SEM. *P<0.05, **P<0.01. Representative lower power image of mid (E) and rostral (F) sections stained with antiamyloid-b40antibody (Scale bar = 500mm) from vehicle treated group. High power surface (e) and parenchymal (f) vessel (Scale bar 25 =mm).
Bales, K. R., O’neill, S. M., Pozdnyakov, N., Pan, F., Caouette, D., Pi, Y., ... & Johnson, A. W. (2015). Passive immunotherapy targeting amyloid-β reduces cerebral amyloid angiopathy and improves vascular reactivity. Brain, 139(2), 563-577.
Figure 3 Enrichment of cerebral vasculature elements from brain tissue and quantification of amyloid-bpeptides following administration of ponezumab.
Enrichment of cerebral vascular elements from brain tissue (A, BH = crude brain homogenate, S = neuronal elements; V = cerebrovascular enriched fraction; eNOS = endothelial nitric oxide, encoded byNos3; PECAM = platelet/endothelial cell adhesion molecule 1; GAPDH = glyceraldehyde dehydrogenase). Significant reduction in detergent soluble amyloid-b40 (B) and amyloid-b42 (C) following 3 months treatment of PSAPP mice with ponezumab (6 months of age at study start; 10 mg/kg, weekly intraperitoneal), *P<0.05. There was no significant reduction in amyloid-b40 (D) or amyloid-b42 (E) levels from the guanidine extractable pool measured from the cerebrovascular enriched fraction;n= 6–7 per group.
Bales, K. R., O’neill, S. M., Pozdnyakov, N., Pan, F., Caouette, D., Pi, Y., ... & Johnson, A. W. (2015). Passive immunotherapy targeting amyloid-β reduces cerebral amyloid angiopathy and improves vascular reactivity. Brain, 139(2), 563-577.
Figure 4 Interstitial fluid levels of amyloid-b40.
Following infusion of a potent gamma secretase inhibitor (Cmpd E; 200 nM; GSI) and peripheral administration of ponezumab (10 mg/kg; intraperitoneal) to APP transgenic mice there was a significant increase in interstitial fluid amyloid-blevels in old plaque bearing mice only (A). Quantification of the change from basal interstitial fluid (ISF) levels over a 30.5–44-h time period after gamma secretase inhibitor infusion and ponezumab administration (B). There is a significant correlation between basal interstitial fluid amyloid-b40 levels and total hippocampal plaque load (both parenchymal and vascular) proximal to the microdialysis probe following treatment (C). (APP = APP K670N;M671L old/young = 18/6 months of age; APP/PS1 = APP K670N;M671L/PS1deltaE9; 12 months of age), n= 3–6 per group (Cirritoet al., 2003).
Bales, K. R., O’neill, S. M., Pozdnyakov, N., Pan, F., Caouette, D., Pi, Y., ... & Johnson, A. W. (2015). Passive immunotherapy targeting amyloid-β reduces cerebral amyloid angiopathy and improves vascular reactivity. Brain, 139(2), 563-577.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Afuco™ Anti-APP ADCC Recombinant Antibody (Ponezumab), ADCC EnhancedThis product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to Abeta. Ponezumab is a humanized monoclonal antibody designed for the treatment of Alzheimer's disease.
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-226 | Anti-Human Abeta Recombinant Antibody (Crenezumab) | WB, IF, IP, Neut, FuncS, ELISA, FC | IgG4 - kappa |
TAB-253CQ | Human Anti-APP Recombinant Antibody (TAB-253CQ) | ELISA | Humanized IgG1 |
TAB-253CQ-S(P) | Human Anti-APP Recombinant Antibody; scFv Fragment (TAB-253CQ-S(P)) | ELISA | Humanized scFv |
TAB-0828CLV | Human Anti-APP Recombinant Antibody (TAB-0828CLV) | ELISA | Humanized antibody |
TAB-0829CLV | Human Anti-APP Recombinant Antibody (TAB-0829CLV) | ELISA | Humanized antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-229 | Anti-Human Abeta Recombinant Antibody (Gantenerumab) | FuncS, IF, Neut, ELISA, FC, IP, ICC | IgG1 - kappa |
TAB-0783CLV-F(E) | Human Anti-APP Recombinant Antibody; Fab Fragment (TAB-0783CLV-F(E)) | ELISA, FuncS | Human Fab |
TAB-0784CLV-F(E) | Human Anti-APP Recombinant Antibody; Fab Fragment (TAB-0784CLV-F(E)) | ELISA | Human Fab |
TAB-0785CLV-F(E) | Human Anti-APP Recombinant Antibody; Fab Fragment (TAB-0785CLV-F(E)) | ELISA | Human Fab |
TAB-0786CLV-F(E) | Human Anti-APP Recombinant Antibody; Fab Fragment (TAB-0786CLV-F(E)) | ELISA | Human Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
PNBL-070 | Recombinant Anti-APP VHH Single Domain Antibody (PNBL-070) | ELISA, Neut, WB, Inhibition | Llama VHH |
TAB-0019CL-VHH | Camelid Anti-APP Recombinant Antibody (TAB-0019CL-VHH) | IHC, WB | Camelid VHH |
TAB-0020CL-VHH | Anti-Human APP VHH Single Domain Antibody (TAB-0020CL-VHH) | ELISA, IHC | Single domain antibody |
TAB-0021CL-VHH | Anti-Human APP VHH Single Domain Antibody (TAB-0021CL-VHH) | ELISA, In vivo, FuncS | Single domain antibody |
TAB-0022CL-VHH | Anti-Human APP VHH Single Domain Antibody (TAB-0022CL-VHH) | ELISA, In vivo, FuncS | Single domain antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
PABW-009 | Mouse Anti-APP Recombinant Antibody (clone PFA1) | ELISA | Mouse IgG2a |
PABC-010 | Mouse Anti-APP Recombinant Antibody (clone PFA2) | ELISA | Mouse IgG2a |
MOB-043LC | Recombinant Mouse Anti-Mouse APP Antibody | WB, IP | Mouse IgG |
PABC-394 | Mouse Anti-APP Recombinant Antibody (clone c#6) | ELISA, WB, FuncS | Mouse IgG1 |
PABC-395 | Mouse Anti-APP Recombinant Antibody (clone c#24) | ELISA, WB, FuncS | Mouse IgG1 |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-254CQ | Human Anti-APP Recombinant Antibody (TAB-254CQ) | ELISA | Chimeric (mouse/human) IgG1 |
TAB-254CQ-S(P) | Mouse Anti-APP Recombinant Antibody; scFv Fragment (TAB-254CQ-S(P)) | ELISA | Mouse scFv |
TAB-0789CLV | Human Anti-APP Recombinant Antibody (TAB-0789CLV) | IP | Chimeric (mouse/human) IgG |
TAB-0802CLV | Human Anti-APP Recombinant Antibody (TAB-0802CLV) | ELISA | Chimeric (mouse/human) IgG1, κ |
TAB-0789CLV-S(P) | Mouse Anti-APP Recombinant Antibody; scFv Fragment (TAB-0789CLV-S(P)) | ELISA | Mouse scFv |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-252CQ-F(E) | Mouse Anti-APP Recombinant Antibody; Fab Fragment (TAB-252CQ-F(E)) | ELISA | Mouse Fab |
TAB-255CQ-F(E) | Mouse Anti-APP Recombinant Antibody; Fab Fragment (TAB-255CQ-F(E)) | ELISA | Mouse Fab |
TAB-0808CLV-F(E) | Mouse Anti-APP Recombinant Antibody; Fab Fragment (TAB-0808CLV-F(E)) | ELISA | Mouse Fab |
TAB-0827CLV-F(E) | Mouse Anti-APP Recombinant Antibody; Fab Fragment (TAB-0827CLV-F(E)) | ELISA | Mouse Fab |
TAB-0792CLV-S(P) | Mouse Anti-APP Recombinant Antibody; scFv Fragment (TAB-0792CLV-S(P)) | ELISA | Mouse scFv |
CAT | Product Name | Application | Type |
---|---|---|---|
BRD-0685MZ | Chicken Anti-APP Polyclonal IgY | IHC | Chicken antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
PABX-014 | Hi-Affi™ Rabbit Anti-APP Recombinant Antibody (clone M204) | WB, ELISA, FuncS | Rabbit IgG |
PABX-014-F (E) | Hi-Affi™ Rabbit Anti-APP Recombinant Antibody (clone M204); Fab Fragment | WB, ELISA, FuncS | Rabbit Fab |
MOR-0220 | Hi-Affi™ Rabbit Anti-APP Recombinant Antibody (clone DS220AB) | ELISA, WB | Rabbit IgG |
MOR-4539 | Hi-Affi™ Rabbit Anti-APP Recombinant Antibody (clone TH47DS) | IHC-P, ELISA | Rabbit IgG |
MOR-0082-FY | Rabbit Anti-APP Recombinant Antibody (clone AFY0053) | ICC, IHC-P, WB | Rabbit IgG |
CAT | Product Name | Application | Type |
---|---|---|---|
EPAF-0566CQ | Mouse Anti-APP Recombinant Antibody (clone 6E10) | ELISA | Mouse IgG |
EPAF-0567CQ | Mouse Anti-APP Recombinant Antibody (clone 4G8) | ELISA, IHC | Mouse IgG2b |
EPAF-0568CQ | Human Anti-APP Recombinant Antibody (clone HyL5) | ELISA, Inhib | Human IgM |
EPAF-0569CQ | Mouse Anti-APP Recombinant Antibody (clone AB1-42) | IHC | Mouse IgG |
EPAF-0570CQ | Human Anti-APP Recombinant Antibody (clone L11.3) | IHC, ELISA, Inhib | Human IgM |
CAT | Product Name | Application | Type |
---|---|---|---|
NS-001CN | Human Anti-APP Recombinant Antibody (clone AS) | WB | Human IgG |
NS-007CN | Mouse Anti-APP Recombinant Antibody (NS-007CN) | ELISA, FuncS | Mouse IgG1 |
NS-001CN-F(E) | Human Anti-APP Recombinant Antibody (clone AS); Fab Fragment | WB | Human Fab |
NS-007CN-F(E) | Mouse Anti-APP Recombinant Antibody; Fab Fragment (NS-007CN-F(E)) | ELISA | Mouse Fab |
NS-001CN-S(P) | Human Anti-APP Recombinant Antibody (clone AS); scFv Fragment | WB | Human scFv |
CAT | Product Name | Application | Type |
---|---|---|---|
HPAB-0116CQ-F(E) | Mouse Anti-APP Recombinant Antibody; Fab Fragment (HPAB-0116CQ-F(E)) | ELISA, WB, IP, FuncS | Mouse Fab |
HPAB-0117CQ-F(E) | Human Anti-APP Recombinant Antibody; Fab Fragment (HPAB-0117CQ-F(E)) | ELISA, WB, IP, FuncS | Human Fab |
HPAB-0118CQ-F(E) | Human Anti-APP Recombinant Antibody (clone Fv1E4); Fab Fragment | ELISA, Inhib | Human Fab |
HPAB-0119CQ-F(E) | Human Anti-APP Recombinant Antibody (clone h12A11v1); Fab Fragment | ELISA, FuncS | Human Fab |
HPAB-0120CQ-F(E) | Human Anti-APP Recombinant Antibody; Fab Fragment (HPAB-0120CQ-F(E)) | ELISA, IHC, FuncS | Human Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
AFC-TAB-225 | Afuco™ Anti-APP ADCC Recombinant Antibody (Bapineuzumab), ADCC Enhanced | FuncS, IF, Neut, ELISA, FC | ADCC enhanced antibody |
AFC-TAB-228 | Afuco™ Anti-APP ADCC Recombinant Antibody (Solanezumab), ADCC Enhanced | FuncS, IF, Neut, ELISA, FC | ADCC enhanced antibody |
AFC-TAB-229 | Afuco™ Anti-APP ADCC Recombinant Antibody (Gantenerumab), ADCC Enhanced | FuncS, IF, Neut, ELISA, FC, IP | ADCC enhanced antibody |
AFC-TAB-227 | Afuco™ Anti-APP ADCC Recombinant Antibody (Ponezumab), ADCC Enhanced | ELISA, IP, FC, FuncS, Neut | ADCC enhanced antibody |
AFC-TAB-226 | Afuco™ Anti-APP ADCC Recombinant Antibody (Crenezumab), ADCC Enhanced | IF, IP, Neut, FuncS, ELISA | ADCC enhanced antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
HPAB-0346-FY-S(P) | Mouse Anti-APP Recombinant Antibody (clone IBL-102); scFv Fragment | Cyt, WB, ELISA | Mouse scFv |
HPAB-1640-FY-F(E) | Human Anti-APP Recombinant Antibody (clone 266); scFv Fragment | Cyt | Humanized scFv |
HPAB-S0004-YC-S(P) | Human Anti-APP Recombinant Antibody (clone hu3D6); scFv Fragment | ELISA, FuncS | Human scFv |
HPAB-S0005-YC-S(P) | Human Anti-APP Recombinant Antibody (clone ch3D6); scFv Fragment | ELISA, FuncS | Human scFv |
HPAB-1828-FY-F(E) | Mouse Anti-APP Recombinant Antibody (clone 2324); scFv Fragment | ELISA | Mouse scFv |
There are currently no Customer reviews or questions for TAB-227. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.